AVDL Avadel Pharmaceuticals ADS

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming virtual investor conferences in September:

  • 2021 Wells Fargo Virtual Healthcare Conference: Fireside chat on Friday, September 10, 2021 at 4:00 p.m. E.T.
  • Morgan Stanley 19th Annual Global Healthcare Conference: Fireside chat on Thursday, September 9, 2021 at 9:30 a.m. E.T.
  • H.C. Wainwright’s 23rd Annual Global Investment Conference: Fireside chat on Monday, September 13, 2021 at 7:00 a.m. E.T.
  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: Fireside chat on Wednesday, September 22, 2021 at 10:45 a.m. E.T.

A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, , for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit .

Investor Contact:

Courtney Turiano

Stern Investor Relations, Inc.



(212) 698-8687

Media Contact:

Nicole Raisch Goelz

Real Chemistry



(408) 568-4292



EN
02/09/2021

Underlying

AVDLAvadel Pharmaceuticals ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avadel Pharmaceuticals ADS

 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing

Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (“Avadel” or the “Company”) announces that the Irish High Court (the “Court”) has today sanctioned, without modification, the scheme of arrangement between Avadel and its shareholders unde...

February 10, 2026 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the ...

Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (“Avadel” or the “Company”) announces today that, in relation to the previously announced offer for the Company by Alkermes plc, a public limited company in...

January 12, 2026 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 R...

Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia - Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the completion of patient enrollment in REVITALYZ, a Phase 3 trial evaluating LUMRYZTM (sodium oxybate) extended-release oral suspension as a potential treatment for idiopathic hypersomnia (IH). REVITALYZ is a double-blind, placebo-controlled, randomized withdrawal, multicen...

December 18, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Announcement relating to despatch of Rule 15 proposal

Announcement relating to despatch of Rule 15 proposal NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors of Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (the “Company” or ...

December 5, 2025 1 EN
 PRESS RELEASE
Free
AVDL Avadel Pharmace...

Announcement relating to despatch of Definitive Proxy Statement and de...

Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 17(B) (AS AMENDED BY SECTION 3 OF APPENDIX 4) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- As previously announced, the board of directors...

December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch